By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neovia Oncology Inc. 



Seattle  Washington    U.S.A.
Phone: 425-298-4099 Fax: n/a


SEARCH JOBS

Neovia develops oncology drugs that enhance immunotherapy response to overcome drug resistance and has begun a Phase 1 clinical trial designed to evaluate our lead multi-inhibitor, (NEV-801), that has the potential to treat patients with advanced drug-resistant cancers.

Normally, immunotherapy rarely controls clinically significant tumors that fail to express target antigens, and thereby fail to elicit an effective immune response. However, there is mounting evidence that tumor antigen production can be deliberately stimulated to promote immune recognition and response.

LEADERSHIP:

Founder and CEO: Trevor Blake

Co-Founder: Raymond Su

COO: Gerald Su

CLINICAL TRIAL:

Please click here for clinical trial information.



Key Statistics


Email: information@neoviaoncology.com
Ownership: Private

Web Site: Neovia Oncology
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->